Theriva Net Debt from 2010 to 2024

TOVX Stock

USD 1.18 0.01 0.84%

Theriva Biologics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2024. Net Debt is the total debt of Theriva Biologics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1993-03-31

Previous Quarter

-14.8 M

Current Value

-14.7 M

Quarterly Volatility

16.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.17. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.

Check out the analysis of Theriva Biologics Correlation against competitors.

For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Theriva Biologics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Theriva Biologics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Theriva Net Debt Regression Statistics

	Arithmetic Mean	(20,224,257)
	Coefficient Of Variation	(77.90)
	Mean Deviation	10,072,096
	Median	(17,525,000)
	Standard Deviation	15,754,482
	Sample Variance	248.2T
	Range	64.1M
	R-Value	(0.54)
	Mean Square Error	189.8T
	R-Squared	0.29
	Significance	0.04
	Slope	(1,896,357)
	Total Sum of Squares	3474.9T

Theriva Net Debt History

	2024	-20 M
	2023	-21 M
	2022	-40.1 M
	2021	-65.8 M
	2020	-5.8 M
	2019	-14.3 M
	2018	-28.9 M

Other Fundumenentals of Theriva Biologics

Net Debt To E B I T D A

Theriva Biologics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Intangible Assets	Common Stock	Good Will	Net Tangible Assets	Net Invested Capital	Capital Stock	Net Working Capital	Property Plant Equipment	Long Term Debt	Deferred Long Term Liab	Short Long Term Debt
Total Assets		0.94	-0.83	-0.76	0.01	0.46	0.81	0.48	0.46	-0.35	0.36	-0.27	0.71	0.91	0.89	-0.92	0.65	0.88	-0.48	-0.46	0.47
Total Stockholder Equity	0.94		-0.84	-0.68	-0.18	0.13	0.81	0.38	0.39	-0.29	0.29	-0.3	0.61	0.87	0.88	-0.9	0.68	0.85	-0.39	-0.37	0.38
Net Debt	-0.83	-0.84		0.56	-0.01	-0.23	-0.98	0.0	0.01	0.32	-0.32	0.06	-0.21	-0.71	-0.84	0.68	-0.84	-0.65	0.01	0.0	0.0
Retained Earnings	-0.76	-0.68	0.56		-0.16	-0.51	-0.55	-0.53	-0.49	0.52	-0.52	0.49	-0.62	-0.56	-0.47	0.74	-0.14	-0.67	0.5	0.46	-0.49
Accounts Payable	0.01	-0.18	-0.01	-0.16		0.55	0.1	-0.1	-0.15	-0.23	0.24	-0.02	-0.14	-0.23	-0.24	0.23	-0.19	-0.18	0.1	0.08	-0.09
Total Liab	0.46	0.13	-0.23	-0.51	0.55		0.25	0.4	0.3	-0.32	0.33	-0.05	0.47	0.32	0.26	-0.3	0.08	0.32	-0.35	-0.33	0.34
Total Current Assets	0.81	0.81	-0.98	-0.55	0.1	0.25		0.03	-0.05	-0.35	0.33	-0.07	0.19	0.66	0.82	-0.64	0.79	0.66	0.05	0.08	-0.07
Short Term Debt	0.48	0.38	0.0	-0.53	-0.1	0.4	0.03		0.84	-0.29	0.21	-0.41	0.85	0.52	0.32	-0.57	-0.17	0.68	-0.82	-0.67	0.75
Net Receivables	0.46	0.39	0.01	-0.49	-0.15	0.3	-0.05	0.84		-0.2	0.22	-0.34	0.8	0.6	0.3	-0.63	-0.05	0.55	-0.98	-0.93	0.96
Short Term Investments	-0.35	-0.29	0.32	0.52	-0.23	-0.32	-0.35	-0.29	-0.2		-0.98	0.8	-0.17	-0.16	-0.13	0.21	0.01	-0.24	0.16	0.11	-0.14
Intangible Assets	0.36	0.29	-0.32	-0.52	0.24	0.33	0.33	0.21	0.22	-0.98		-0.81	0.18	0.16	0.12	-0.22	0.02	0.18	-0.18	-0.18	0.19
Common Stock	-0.27	-0.3	0.06	0.49	-0.02	-0.05	-0.07	-0.41	-0.34	0.8	-0.81		-0.38	-0.07	0.02	0.21	0.27	-0.21	0.31	0.29	-0.3
Good Will	0.71	0.61	-0.21	-0.62	-0.14	0.47	0.19	0.85	0.8	-0.17	0.18	-0.38		0.71	0.54	-0.77	0.11	0.76	-0.8	-0.76	0.79
Net Tangible Assets	0.91	0.87	-0.71	-0.56	-0.23	0.32	0.66	0.52	0.6	-0.16	0.16	-0.07	0.71		0.93	-0.94	0.73	0.88	-0.61	-0.58	0.6
Net Invested Capital	0.89	0.88	-0.84	-0.47	-0.24	0.26	0.82	0.32	0.3	-0.13	0.12	0.02	0.54	0.93		-0.87	0.85	0.87	-0.29	-0.26	0.28
Capital Stock	-0.92	-0.9	0.68	0.74	0.23	-0.3	-0.64	-0.57	-0.63	0.21	-0.22	0.21	-0.77	-0.94	-0.87		-0.56	-0.92	0.61	0.58	-0.6
Net Working Capital	0.65	0.68	-0.84	-0.14	-0.19	0.08	0.79	-0.17	-0.05	0.01	0.02	0.27	0.11	0.73	0.85	-0.56		0.5	0.03	-0.01	-0.01
Property Plant Equipment	0.88	0.85	-0.65	-0.67	-0.18	0.32	0.66	0.68	0.55	-0.24	0.18	-0.21	0.76	0.88	0.87	-0.92	0.5		-0.54	-0.43	0.49
Long Term Debt	-0.48	-0.39	0.01	0.5	0.1	-0.35	0.05	-0.82	-0.98	0.16	-0.18	0.31	-0.8	-0.61	-0.29	0.61	0.03	-0.54		0.96	-0.99
Deferred Long Term Liab	-0.46	-0.37	0.0	0.46	0.08	-0.33	0.08	-0.67	-0.93	0.11	-0.18	0.29	-0.76	-0.58	-0.26	0.58	-0.01	-0.43	0.96		-0.99
Short Long Term Debt	0.47	0.38	0.0	-0.49	-0.09	0.34	-0.07	0.75	0.96	-0.14	0.19	-0.3	0.79	0.6	0.28	-0.6	-0.01	0.49	-0.99	-0.99

Click cells to compare fundamentals

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-21 M	-20 M
Net Debt To EBITDA	1.06	0.66

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Theriva Net Debt from 2010 to 2024

Latest Theriva Biologics' Net Debt Growth Pattern

Theriva Net Debt Regression Statistics

Theriva Net Debt History

Other Fundumenentals of Theriva Biologics

Theriva Biologics Net Debt component correlations

About Theriva Biologics Financial Statements

Also Currently Popular

Additional Tools for Theriva Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY